Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.

Cardiovasc Diabetol · 2019 · PMC6805385 · PMID 31640705

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

A p-value < 0.05 was considered nominally significant. eGFR slope eGFR slope vs. time was analyzed in both sets of propensity-matched cohorts using a mixed-model repeated measures (MMRM) analysis to estimate the overall treatment effect on eGFR slope.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.